Neurocognitive changes in a patient receiving esketamine for treatment-resistant depression.
JAAPA : official journal of the American Academy of Physician Assistants September 1, 2024 Carolyn F Kundert, Robert M Sobule, Muaid Ithman 1 citation
Esketamine, the s(+) enantiomer of ketamine, was approved in 2019 as the first rapid-acting intranasal spray medication for treatment-resistant depression; the drug is given in combination with an antidepressant. The treatment is self-administered in a clinical setting under the supervision of a healthcare provider and usually is well tolerated. Many of its adverse reactions are mild,...